Olodaterol
- Generic Name
- Olodaterol
- Brand Names
- Inspiolto Respimat, Stiolto, Striverdi Respimat
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26N2O5
- CAS Number
- 868049-49-4
- Unique Ingredient Identifier
- VD2YSN1AFD
- Background
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel i...
- Indication
Olodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
- Associated Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- -
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift
FDA expands DUPIXENT use for COPD, offering new treatment options for patients. COPD affects 44 million in 7MM, with cases expected to rise. DUPIXENT targets IL-4 and IL-13 pathways, reducing exacerbations and improving lung function.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath